

Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. *J Rheumatol* 2009;36:398-409.

Page 404; the subsection Patient global assessment should read: “*Patient global assessment.* Patients receiving both doses of milnacipran reported greater overall improvements in terms of their FM based on the PGIC at Week 15 compared to placebo (milnacipran 200 mg/day, $p < 0.001$; milnacipran 100 mg/day, $p = 0.009$; Table 3). PGIC scores for patients on milnacipran 200 mg/day were significantly improved over patients on placebo at 27 weeks ($p < 0.001$). On an OC basis, the PGIC response rate at 15 weeks favored milnacipran, with 78% ($p < 0.001$) and 76% ($p = 0.006$) of patients on 200 mg/day and 100 mg/day, respectively, achieving PGIC responder criteria (“very much improved,” “much improved,” or “minimally improved”), compared to a placebo response rate of 61%. PGIC responder rates for patients rating themselves as “very much improved” or “much improved” at 15 weeks were 55% ($p < 0.001$) and 53% ($p = 0.007$) for 200 mg/day and 100 mg/day, respectively, compared to a placebo response rate of 37%. Improvements on the PGIC were statistically significant at every clinic visit after randomization for patients on both doses of milnacipran (LOCF; $p < 0.05$).”

Page 406, paragraph 2, line 7, should read “On average, after 6 months of treatment, patients on milnacipran 200 and 100 mg/day lost more weight (−1.50 lb, $p = 0.0012$; −2.02 lb, $p < 0.001$, respectively) compared to placebo-treated patients (+0.73 lb).”

Page 408, Acknowledgment of Investigators should have included Christopher Alftine, MD; Floyd Anderson, MD; Lesley Arnold, MD; Andrew Baldassare, MD; Mira Baron, MD; Patricia Buchanan, MD; Stephen Burnstein, DO; Sylvia Cerel, MD; John Condemi, MD; Daniel Dionne, MD; Don Goldenberg, MD; Jerry Green, MD; Wayne Harper, MD; Anita Kablinger, MD; Jeffery Lieberman, MD; John LaFata, MD; Harris McIlwain, MD; Kenneth Nies, MD; John Pappas, MD; Richard Pellegrino, MD, PhD; Philippe Saxe, MD; Dana Trotter, MD; Bridget Walsh, DO; Nathan Wei, MD; Hayes Williams, MD, PhD. We regret the errors.

doi:10.3899/jrheum.080734C1